Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks.

Area of Science:

• Neuroscience
• Anesthesiology
• Pharmacology

Background:

• Panic disorder is characterized by recurrent panic attacks involving emotional and cardiovascular responses.
• The dorsomedial hypothalamus (DMH) is implicated in the brain circuitry of panic attacks.
• The endocannabinoid system, particularly 2-arachidonoylglycerol (2-AG), is known to modulate hypothalamic functions.

Purpose of the Study:

• To investigate the role of hypothalamic endocannabinoid signaling in controlling aversive responses related to panic attacks.
• To test the hypothesis that 2-AG signaling in the DMH influences panic-like behaviors and associated physiological responses.

Main Methods:

• A rat model was used, inducing panic-like behavior via NMDA infusion into the DMH.
• The effects of a monoacylglycerol lipase (MAGL) inhibitor (URB602) and a fatty acid amide hydrolase (FAAH) inhibitor (URB597) on panic-like behavior were assessed.
• Cannabinoid receptor 1 (CB1) and CB2 antagonists (AM251, AM630) and agonists (ACEA, JWH133) were used to explore receptor involvement.
• Cardiovascular responses to DMH stimulation were measured in anesthetized rats.

Main Results:

• Local DMH infusion of the MAGL inhibitor URB602 prevented NMDA-induced panic-like behavior, while the FAAH inhibitor URB597 was ineffective.
• The anti-aversive effect of URB602 was blocked by CB1 and CB2 antagonists and mimicked by CB1 and CB2 agonists.
• URB602 administration also attenuated the cardiovascular effects of DMH stimulation.
• No significant changes in blood corticosterone levels were observed across treatments.

Conclusions:

• Facilitation of 2-AG signaling within the DMH plays a crucial role in modulating panic-like responses.
• This modulation appears to involve the activation of both CB1 and CB2 cannabinoid receptors in the DMH.
• Hypothalamic endocannabinoid signaling represents a potential therapeutic target for panic disorder.